AIBT AIBOTICS THERAPIES, INC.
Medicinal Chemicals & Botanical Products · OTC · SEC CIK 1763329 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY-100.0%
TTM net income YoY-3.2%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-241.3%
ROIC (approx.)—
Asset turnover0.00x
Leverage & solvency
Liabilities / assets937.3%
Debt / equity—
Current ratio0.05x
Interest coverage-9.75x
Cash quality & payout
Operating cash flow / net income0.17x
Accruals ratio-201.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $2,183 | $0 | — | — | — |
| Gross profit | $2,183 | $0 | — | — | — |
| SG&A expense | $1.85M | $1.63M | $616,724 | $1.74M | $4.99M |
| Operating income | -$1.84M | -$1.63M | -$616,724 | -$1.74M | -$4.99M |
| Interest expense | $226,902 | $213,458 | $564,623 | $863,330 | $143,057 |
| Pretax income | -$2.22M | -$1.85M | -$1.18M | -$2.61M | -$5.14M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$2.22M | -$1.85M | -$1.18M | -$2.61M | -$5.14M |
| EBITDA | -$1.84M | -$1.63M | -$615,726 | -$1.74M | -$4.99M |
| EPS (diluted) | — | — | — | — | — |
| Weighted avg. shares (diluted) | — | — | — | — | 13.41M |
| Balance sheet | |||||
| Cash & equivalents | $255,940 | $185,097 | $279,134 | $385,899 | $1.27M |
| Inventory | $0 | — | — | — | — |
| Current assets | $270,107 | $185,097 | $279,134 | $385,899 | $1.27M |
| PP&E, net | $0 | $0 | $498 | $1,496 | $2,497 |
| Intangibles | — | $1.27M | — | — | — |
| Total assets | $874,673 | $1.46M | $2.22M | $387,395 | $1.27M |
| Current liabilities | $4.79M | $4.85M | $4.25M | $764,513 | $594,370 |
| Total liabilities | $4.83M | $4.85M | $4.25M | $1.28M | $1.22M |
| Shareholders' equity | -$3.96M | -$3.39M | -$2.03M | -$891,348 | $52,021 |
| Shares outstanding | 486.90M | 39.99M | 14.90M | 14.86M | 13.97M |
| Cash flow statement | |||||
| Operating cash flow | -$458,240 | -$259,037 | -$106,765 | -$656,620 | -$235,482 |
| Capital expenditure | — | — | — | $0 | $2,746 |
| Free cash flow | — | — | — | -$656,620 | -$238,228 |
| Investing cash flow | — | — | $0 | $0 | -$2,746 |
| Financing cash flow | $529,083 | $165,000 | $0 | -$225,000 | $1.40M |
| Depreciation & amortization | $0 | $498 | $998 | $1,001 | $249 |
| Stock-based compensation | — | $0 | $635 | $1.02M | $4.31M |
Free plan shows the latest 5 periods; Pro shows all 8 🔒
· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.